LLY_OUT_1 [2025-04-17 12:58:36 -0400] 3668 Bytes | 997 tokens | Cum: 997 tkns (12.46% of 8k)
==========================================================================

We're scouting for winners today. Its 12:58:35 PM on Thu Apr 17, 2025 -0400 and I'm looking at Eli Lilly & (LLY) up to 854.5100 from 734.9000

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Eli Lilly & (LLY)
IPO: 1970-07-09 (54 Years Ago)
Market Cap: $649,821,503,427
Shares Outstanding: 947,990,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNYS
Description: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Here’s a list of headlines for Eli Lilly &:

Today 12:46PM - Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
12:45PM - Top Stock Movers Now: UnitedHealth, Nvidia, Eli Lilly and More
12:17PM - Eli Lillys shares up as oral GLP-1RA scores in first Phase III trial
12:01PM - Why Is Eli Lilly (LLY) Stock Rocketing Higher Today
11:46AM - Stocks Flounder Amid Trumps Fed Rebuke, Trade War: Markets Wrap
11:36AM - Wall Street Lunch: Obesity Pill Progress
11:24AM - Eli Lilly Rockets 15% After Solidifying Its Lead For A Weight-Loss Pill
11:20AM - Eli Lilly's weight loss pill could be just as good as Ozempic and the stock soars

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-15T14:15:00Z - Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?
B2 - 2025-04-14T15:12:30Z - Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
B3 - 2025-04-11T13:36:46Z - Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties
B4 - 2025-04-11T11:00:00Z - Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
B5 - 2025-04-10T15:00:00Z - Injectable Drug Delivery Devices Market Size to Reach USD 1,217 Bn by 2034: Statifacts
B6 - 2025-04-10T09:59:00Z - Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Eli Lilly & (LLY).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

LLY_OUT_3 [2025-04-17 12:58:36 -0400] 796 Bytes | 223 tokens | Cum: 1222 tkns (15.28% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today**Date: Unknown DateSource: Unknown SourceURL: https://www.fool.com/investing/2025/04/14/eli-lilly-novo-nordisk-viking-therapeutics-all-pop/?source=iedfolrf0000001Pfizer announced it will discontinue development of its oral GLP-1 weight loss pill danuglipron due to the risk of liver injury. This news benefits Eli Lilly, Novo Nordisk, and Viking Therapeutics, who are now in a better position in the GLP-1 weight loss drug market.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LLY_OUT_5 [2025-04-17 12:58:37 -0400] 964 Bytes | 257 tokens | Cum: 1481 tkns (18.51% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-17T15:10:16Z - Eli Lilly Stock Surges on Weight-Loss Drug Trial Success - Schaeffer's Investment Research...
A2 - 2025-04-17T11:55:48Z - Eli Lilly's stock soars as successful trial of weight-loss pill is a game changer...
A3 - 2025-04-16T09:33:00Z - Viking Therapeutics Stock Pops But Struggles to Hold Gains...
A4 - 2025-04-14T20:48:08Z - Trump administration initiates probes on semiconductor and pharmaceutical imports By Investing.com...
A5 - 2025-04-14T20:48:08Z - Trump administration initiates probes on semiconductor and pharmaceutical imports By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

LLY_OUT_7 [2025-04-17 12:58:39 -0400] 1181 Bytes | 321 tokens | Cum: 1804 tkns (22.55% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Eli Lilly Stock Surges on Weight-Loss Drug Trial Success - Schaeffer's Investment Research**Date: 2025-04-17Source: {'uri': 'schaeffersresearch.com', 'dataType': 'news', 'title': 'Schaeffers Investment Research'}URL: https://www.schaeffersresearch.com/content/news/2025/04/17/eli-lilly-stock-surges-on-weight-loss-drug-trial-successEli Lilly & Co (NYSE:LLY) stock is headed for its best day since August 2023, last seen up 13.4% at $838.48 at last check, after the pharmaceutical giant reported positive results for a phase 3 trial of its weight-loss drug, orforglipron. The experimental pill resulted in weight loss of nearly 8% at the highest dose, and lowered blood sugar in patients with type 2 diabetes.

Today's pop helped Eli Lilly stock fully recover from its early April bear gap, and has it back in positive territory for 2025. LLY was overdue for a bounce, as its 14-day relative str

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LLY_OUT_9 [2025-04-17 12:58:39 -0400] 1083 Bytes | 284 tokens | Cum: 2090 tkns (26.12% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): ength index (RSI) of 30 sits just in "oversold" territory. The shares are now grappling with familiar pressure at the $840 level, which is home to a confluence of long-term moving averages.

Over in the options pits, LLY has seen 45,000 calls and 35,000 puts cross the tape so far today, which is already 8 times the stock's overall average daily options volume. Expiring today, the April 800 put and 900 call are the most popular, with new positions opening at both.

This penchant for calls shows a shift in sentiment. LLY's 10-day put/call volume ratio of 1.01 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits higher than 87% of readings from the past year, showing puts were picked up at a faster-than-usual rate in the last two weeks.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LLY_OUT_11 [2025-04-17 12:58:41 -0400] 238 Bytes | 59 tokens | Cum: 2151 tkns (26.89% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

LLY_OUT_13 [2025-04-17 12:58:49 -0400] 8560 Bytes | 2568 tokens | Cum: 4721 tkns (59.01% of 8k)
==========================================================================

This is our set of metrics for Eli Lilly &.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-----------------------+
| Volume: 6,872,790 | Perf Month: 1.99% | Option/Short: Yes / Yes | Sales Y/Y TTM: 32.00% |
+-------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 3.64M | Perf Quarter: 12.68% | Short Float: 0.83% | ROE: 84.84% |
+-------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 3.63 | Index: S&P 500 | Short Ratio: 1.93 | ROI: 24.79% |
+-------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 59.64 | Market Cap: 809.25B | Short Interest: 7.02M | Sales Surprise: 0.44% |
+-------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 39.31 | Shs Outstand: 947.54M | Beta: 0.54 | EPS Surprise: 5.45% |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 8.33% | Shs Float: 849.99M | Sales Q/Q: 44.68% | P/E: 74.30 |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA50: 2.12% | Inst Own: 72.97% | Sales past 5Y: 15.54% | Earnings: May 01 BMO |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA200: 0.75% | Insider Own: 10.34% | Employees: 47000 | |
+-------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 18.41% | Insider Trans: -0.89% | Debt/Eq: 2.37 | |
+-------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by Eli Lilly & officers or majority shareholders (if available).

Inside Trans: ELI LILLY & Co (LLY) by Sulzberger Gabrielle (Unknown Title) on 2025-03-17
- Common Stock: 6.012 shares at $824.76 (D)

Inside Trans: ELI LILLY & Co (LLY) by LUCIANO JUAN R (Unknown Title) on 2025-03-17
- Common Stock: 17.985 shares at $824.76 (D)

Inside Trans: ELI LILLY & Co (LLY) by Hedley Mary Lynne (Unknown Title) on 2025-03-17
- Common Stock: 12.024 shares at $824.76 (D)

Inside Trans: ELI LILLY & Co (LLY) by Fyrwald J Erik (Unknown Title) on 2025-03-17
- Common Stock: 12.024 shares at $824.76 (D)

Inside Trans: ELI LILLY & Co (LLY) by Alvarez Ralph (Unknown Title) on 2025-03-17
- Common Stock: 14.246 shares at $824.76 (D)

Inside Trans: ELI LILLY & Co (LLY) by Zakrowski Donald A (SVP, Finance, & CAO) on 2025-03-13
- Common Stock: 1000 shares at $818.24 (D) Footnote: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2024.

Inside Trans: ELI LILLY & Co (LLY) by LILLY ENDOWMENT INC (Unknown Title) on 2025-03-03
- Common Stock: 18828 shares at $922.421 (D)
- Common Stock: 8197 shares at $923.253 (D)
- Common Stock: 7665 shares at $924.529 (D)
- Common Stock: 3691 shares at $925.554 (D)
- Common Stock: 8401 shares at $927.028 (D)
- Common Stock: 21025 shares at $927.81 (D)
- Common Stock: 25984 shares at $928.984 (D)
- Common Stock: 68251 shares at $929.725 (D)
- Common Stock: 25057 shares at $930.74 (D)
- Common Stock: 17393 shares at $931.817 (D)
- Common Stock: 10699 shares at $932.77 (D)
- Common Stock: 3997 shares at $933.735 (D)
- Common Stock: 812 shares at $934.889 (D)

Inside Trans: ELI LILLY & Co (LLY) by Dozier Eric (EVP, Chief People Officer) on 2025-03-01
- Common Stock: 2403 shares at $0 (D)
- Common Stock: 1066.212 shares at $920.63 (D)
- Restricted Stock Unit: 2403 shares at $0 (D)

Inside Trans: ELI LILLY & Co (LLY) by Hernandez Edgardo (EVP & Pres., Mfg. Operations) on 2025-03-01
- Common Stock: 2837 shares at $0 (D)
- Common Stock: 1260.325 shares at $920.63 (D)
- Restricted Stock Unit: 2837 shares at $0 (D)

Inside Trans: ELI LILLY & Co (LLY) by LILLY ENDOWMENT INC (Unknown Title) on 2025-02-25
- Common Stock: 35578 shares at $900.501 (D)
- Common Stock: 50118 shares at $901.566 (D)
- Common Stock: 47905 shares at $902.486 (D)
- Common Stock: 36219 shares at $903.484 (D)
- Common Stock: 18159 shares at $904.54 (D)
- Common Stock: 11143 shares at $905.412 (D)
- Common Stock: 8559 shares at $906.46 (D)
- Common Stock: 4962 shares at $907.286 (D)
- Common Stock: 5191 shares at $908.292 (D)
- Common Stock: 3290 shares at $909.383 (D)
- Common Stock: 3606 shares at $910.533 (D)
- Common Stock: 270 shares at $911.549 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 45042700000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 10590000000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 854.6608
Average Volume: 3807667.26
30-Day High: 864.9
30-Day Low: 720.91

[Detailed Financials: TTM 2024]
- Total Assets: $78,714,900,000.0
- Total Liabilities: $64,443,300,000.0
- Total Equity: $14,271,600,000.0
- Current Assets: $32,739,700,000.0
- Current Liabilities: $28,376,600,000.0

[Income Statement: TTM 2024]
- Revenue: $45,042,700,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 11.76

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $449,800,000.0

[Detailed Financials: FY 2024]
- Total Assets: $78,714,900,000.0
- Total Liabilities: $64,443,300,000.0
- Total Equity: $14,271,600,000.0
- Current Assets: $32,739,700,000.0
- Current Liabilities: $28,376,600,000.0

[Income Statement: FY 2024]
- Revenue: $45,042,700,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 11.76

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $449,800,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Eli Lilly & (LLY).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Eli Lilly &.

2) MARKET_SCORE[]
This conversation was initiated because LLY is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for LLY.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, LLY could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect LLY to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Eli Lilly &.

11) ETHICAL_RATING[]
Rate Eli Lilly &’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Eli Lilly &.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

LLY_IN_15 [2025-04-17 12:58:49 -0400] 126 Bytes | 29 tokens | Cum: 5016 tkns (62.70% of 8k)
==========================================================================

====================================
[2025-04-17 12:58:49] # Analysis Completed
Elapsed Time: 14.75 seconds